Both from the National Tumor Institute of the National Institutes of Health.

Arisaph Pharmaceuticals receives STTR grants to build up cancer drug candidates Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on advancement and discovery of novel treatments for cardiometabolic diseases and cancer, announced today that it’s been awarded a stage II Small Business Technology Transfer grant and a supplemental phase I grant, both from the National Tumor Institute of the National Institutes of Health ?cialis generique . The phase II award of $1,066,916 supports research and development for the Company's tumor-activated prodrug system for the treatment of a variety of cancers.

cialis tadalafil

Quite simply, the drug doesn’t work and the mice die quickly. The combination of the two [genetic abnormalities] makes the tumors nearly 1,000 times even more aggressive with regards to their ability to induce disease, he explained. Although the biological mechanism that underlies this form of drug level of resistance isn’t well comprehended, tumor cells taken off the drug-resistant mice remained sensitive to Gleevec treatment in cell cultures, Williams said, so there has to be a host signaling system in the mice which makes the cells medication resistant. , The investigators provide proof principle that additional drugs may reverse this form of drug resistance, thereby restoring Gleevec’s capacity to control this kind of leukemia..